Whitney Ijem
Stock Analyst at Canaccord Genuity
(2.04)
# 2,875
Out of 4,734 analysts
84
Total ratings
32.39%
Success rate
-2.38%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $80 | $54.54 | +46.68% | 5 | Nov 19, 2024 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $39 | $10.31 | +278.27% | 5 | Nov 19, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $90 | $9.50 | +847.37% | 5 | Nov 19, 2024 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $6 → $8 | $1.53 | +422.88% | 8 | Nov 15, 2024 | |
| PASG Passage Bio | Maintains: Buy | $13 | $0.60 | +2,066.67% | 6 | Nov 14, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $121 | $40.00 | +202.50% | 7 | Nov 12, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $148 → $150 | $118.00 | +27.12% | 3 | Nov 7, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $29 → $32 | $6.14 | +421.17% | 4 | Nov 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sell | $361 → $408 | $422.00 | -3.32% | 7 | Nov 6, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $366 → $384 | $246.27 | +55.93% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $93 → $84 | $61.53 | +36.52% | 8 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 | $1.40 | +1,042.86% | 5 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $28 | $1.24 | +2,158.06% | 4 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $86 | $16.79 | +412.21% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $0.95 | +849.37% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $91.84 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $16 | $0.66 | +2,323.88% | 4 | Jul 23, 2019 |
Rhythm Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $80
Current: $54.54
Upside: +46.68%
Rocket Pharmaceuticals
Nov 19, 2024
Maintains: Buy
Price Target: $39
Current: $10.31
Upside: +278.27%
Intellia Therapeutics
Nov 19, 2024
Maintains: Buy
Price Target: $90
Current: $9.50
Upside: +847.37%
Taysha Gene Therapies
Nov 15, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.53
Upside: +422.88%
Passage Bio
Nov 14, 2024
Maintains: Buy
Price Target: $13
Current: $0.60
Upside: +2,066.67%
Ultragenyx Pharmaceutical
Nov 12, 2024
Maintains: Buy
Price Target: $121
Current: $40.00
Upside: +202.50%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $148 → $150
Current: $118.00
Upside: +27.12%
Verve Therapeutics
Nov 6, 2024
Maintains: Buy
Price Target: $29 → $32
Current: $6.14
Upside: +421.17%
Vertex Pharmaceuticals
Nov 6, 2024
Maintains: Sell
Price Target: $361 → $408
Current: $422.00
Upside: -3.32%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Buy
Price Target: $366 → $384
Current: $246.27
Upside: +55.93%
Oct 30, 2024
Maintains: Hold
Price Target: $93 → $84
Current: $61.53
Upside: +36.52%
Oct 18, 2024
Maintains: Buy
Price Target: $16
Current: $1.40
Upside: +1,042.86%
Jun 25, 2024
Maintains: Buy
Price Target: $11 → $28
Current: $1.24
Upside: +2,158.06%
May 10, 2024
Maintains: Buy
Price Target: $87 → $86
Current: $16.79
Upside: +412.21%
Nov 8, 2022
Initiates: Buy
Price Target: $9
Current: $0.95
Upside: +849.37%
Jan 21, 2020
Downgrades: Neutral
Price Target: n/a
Current: $91.84
Upside: -
Jul 23, 2019
Upgrades: Overweight
Price Target: $8 → $16
Current: $0.66
Upside: +2,323.88%